Vial
Hyper scalable biotech advancing programs into the clinic with lower cost trials and computationally designed therapeutics
Website: https://vial.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Vial |
| Tagline | Hyper scalable biotech advancing programs into the clinic with lower cost trials and computationally designed therapeutics |
| Headquarters | San Francisco, United States |
| Founded | 2020 |
| Stage | Series A |
| Business Model | B2B |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2): Andrew Brackin, Simon Burns |
| Funding Label | $50M+ |
| Total Disclosed | ~$67,000,000 |
Links
PUBLIC
- Website: https://vial.com
- LinkedIn: https://www.linkedin.com/company/vialtrials
- Crunchbase: https://www.crunchbase.com/organization/vial
- Careers (Lever): https://jobs.lever.co/Vial
Executive Summary
PUBLIC
Vial is a San Francisco-based contract research organization (CRO) that pairs a software-first operating model with a biotech development arm, aiming to compress the cost and timelines of running clinical trials for sponsor companies [Crunchbase News]. Founded in 2020 by Andrew Brackin and Simon Burns, the company has built therapeutic-area expertise across oncology, gastroenterology, and dermatology, and frames itself publicly as a "next generation pharma company powered by computationally designed therapeutics and automated trials" [Vial; General Catalyst]. The founding pair were early team members at Robinhood, Opendoor, and Newfront, and have recruited operators from Apple, Google, Faire, Chime, and TPG Capital to fill out the early team [Vial job description via drawerrr.com]. Vial has raised approximately $67 million led by General Catalyst, with participation from Byers Capital and BoxGroup [Crunchbase News]. Headcount is reported at roughly 179 employees as of late 2024 [LeadIQ] (estimated based on a single third-party tracker), positioning the company at meaningful operating scale for a Series A CRO challenger. Over the next 12 to 18 months, the data points worth tracking are sponsor concentration in the trial book, the cadence of in-house pipeline disclosures, and whether the platform produces measurable cycle-time advantages versus incumbent CROs such as Medable and Science 37 [CBInsights].
Data Accuracy: GREEN -- Confirmed by Crunchbase News, General Catalyst, and the Vial company website.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B (sponsor-paid clinical trial services) |
| Industry / Vertical | Healthtech / Clinical Research |
| Technology Type | Biotech / Life Sciences with software-enabled trial operations |
| Geography | North America (HQ San Francisco) |
| Growth Profile | Venture Scale |
| Founding Team | Two co-founders, technology operator backgrounds |
| Funding | ~$67M disclosed, lead General Catalyst |
Company Overview
PUBLIC
Vial was founded in 2020 in San Francisco by Andrew Brackin and Simon Burns, both of whom held early roles at venture-scale technology companies before turning to clinical research [Startup Intros; PitchBook]. The founding thesis, as articulated by lead investor General Catalyst, was that traditional CROs operate on legacy software and labor-heavy processes, and that a CRO built from the ground up around modern tooling could deliver "faster and more efficient trials for biotech sponsors" across multiple therapeutic areas [General Catalyst].
In the years since launch, Vial has built operational expertise in oncology, gastroenterology, and dermatology, and has expanded its site network through partnerships including the addition of NEXT Oncology, disclosed alongside its $67 million financing round [FierceBiotech]. The company describes itself on its website as a "hyper scalable biotech" and on LinkedIn as a CRO "reimagining clinical trials to deliver faster, more efficient trial results at dramatically lower costs for biotech sponsors" [Vial; LinkedIn]. The dual identity, part services CRO and part in-house drug developer, is unusual in the category and shapes how investors should read the financing.
The company's most material public milestone to date is the $67 million round led by General Catalyst, with Byers Capital and BoxGroup participating [Crunchbase News]. FierceBiotech characterized the round as a Series B, while Crunchbase tags the financing under the company's Series A label, and the public record does not cleanly reconcile the two [FierceBiotech; Crunchbase]. Investors should treat the round structure as something to confirm directly with the company.
Data Accuracy: GREEN -- Confirmed by Crunchbase News, General Catalyst, and FierceBiotech.
Product and Technology
MIXED
Vial's commercial product is a full-service CRO offering aimed at biotech sponsors running interventional trials, with stated specialization in oncology, gastroenterology, and dermatology [PUBLIC; General Catalyst]. The company's marketing positions the platform as enabling "faster, more efficient trial results at dramatically lower costs" through a software layer that handles trial operations, site coordination, and data capture [PUBLIC; LinkedIn]. Alongside the services business, Vial publicly describes a pharma development arm "powered by computationally designed therapeutics and automated trials," indicating the company also intends to advance internal programs into the clinic [PUBLIC; Vial].
The specific technology stack underlying the platform is not disclosed in detail in the cited public materials. Open roles on Lever for a Clinical Trial Lead, a Scientific Writer, and a Chief of Staff suggest the operating model still relies on a meaningful services layer staffed by clinical-operations professionals rather than pure software automation [PUBLIC; Lever.co]. The therapeutic-area focus on oncology and dermatology is consistent with a sponsor base weighted toward small and mid-cap biotechs, where the cost compression pitch is most acute (inferred from job postings and General Catalyst's investment memo).
What is genuinely differentiated, on the evidence available, is the integrated structure: a CRO that simultaneously runs sponsor trials and develops its own pipeline. That structure can produce useful feedback loops between operational data and program design, but it also raises questions about channel conflict that the public record does not yet resolve [MIXED; General Catalyst].
Data Accuracy: YELLOW -- Product positioning confirmed by Vial website and LinkedIn; technology specifics partially corroborated by job postings only.
Market Research and Opportunity
PUBLIC
Clinical trial services is one of the largest and most structurally inefficient segments of healthcare spending, and the case for a software-first challenger rests on whether sponsor economics have deteriorated enough to force a vendor switch.
The global contract research organization market is large and concentrated among a handful of incumbents including IQVIA, Labcorp Drug Development (formerly Covance), Parexel, ICON, and Syneos. Public sizing for the segment is not contained in the cited research set for this report, so investors should treat market-size figures as something to source independently before underwriting. What the cited evidence does establish is that General Catalyst, in its public investment note, frames the opportunity as reimagining a category where "traditional clinical trials are slow, expensive and inefficient" for biotech sponsors specifically [General Catalyst]. That framing matters: the wedge is not enterprise pharma but the long tail of venture-funded biotechs running early-phase studies, where decision cycles are shorter and software-mediated workflows face less institutional resistance.
Demand drivers visible in the public record include the post-2021 compression in biotech funding, which has pushed sponsors to demand lower trial costs per patient enrolled, and the documented difficulty of patient recruitment in oncology and rare disease, where Vial has built therapeutic-area depth [General Catalyst; FierceBiotech]. The addition of NEXT Oncology to Vial's network, disclosed with the $67 million round, is a concrete example of the supply-side build-out needed to compete with established site networks [FierceBiotech]. Adjacent and substitute markets include decentralized clinical trial platforms (where Medable and Science 37 operate) and traditional full-service CROs; Vial's model overlaps both but is not a pure substitute for either [CBInsights].
Regulatory and macro forces cut both ways. The U.S. FDA's continued openness to decentralized and hybrid trial designs is a tailwind for tech-enabled CROs, while the broader biotech funding environment, which has been uneven since 2022, directly affects the pool of sponsors able to commit to multi-site studies. Investors evaluating Vial should weigh the company's exposure to early-stage biotech sponsor budgets as both the source of its differentiation and its primary cyclical risk.
| Cited claim | Value | Source |
|---|---|---|
| Vial total disclosed funding | ~$67,000,000 | [Crunchbase News] |
| Reported headcount, late 2024 | ~179 employees (estimated) | [LeadIQ] |
| Therapeutic areas of stated expertise | Oncology, GI, Dermatology | [General Catalyst] |
The table above captures the only quantitative anchors the public record currently supports for Vial; market-size figures should be sourced independently from a named industry report before being used in underwriting.
Data Accuracy: YELLOW -- Demand drivers and positioning corroborated by General Catalyst and FierceBiotech; no third-party TAM figure was located in the cited research set.
Competitive Landscape
MIXED
Vial competes against two distinct cohorts: legacy full-service CROs that own the sponsor relationship today, and a smaller group of technology-forward trial platforms that have raised meaningful capital on a similar reimagining thesis.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Vial | Tech-enabled CRO plus in-house pipeline | Series A, ~$67M disclosed | Integrated CRO and computationally designed therapeutics | [Crunchbase News; Vial] |
| Medable | Decentralized clinical trial software platform | Late stage, prior unicorn valuation reported in trade press | Software-only DCT platform sold to pharma and CROs | [CBInsights] |
| Science 37 | Decentralized trial operator, publicly traded | Public company (NASDAQ) | Operator model with virtual site network | [CBInsights] |
Within the segment-by-segment map, the legacy incumbents (IQVIA, Labcorp, Parexel, ICON, Syneos) own the large-pharma sponsor relationship and the regulatory track record that comes with thousands of completed trials. Challengers split into two camps: pure software vendors such as Medable, which sell into both sponsors and other CROs, and operator-led models such as Science 37 and Vial, which take on trial execution directly [CBInsights]. Vial's wrinkle is the addition of an internal pipeline arm, which is closer in spirit to a Roivant-style structure than to a conventional CRO.
Vial's defensible edge today, on the public evidence, is twofold. First, the company's sponsor-side pitch, lower cost per enrolled patient through software-mediated operations, is well-aligned with the budget realities facing venture-funded biotechs after the 2022-2024 funding compression [General Catalyst]. Second, the integration of a site network like NEXT Oncology gives Vial supply-side control in a therapeutic area where patient recruitment is the binding constraint [FierceBiotech]. The durability of those edges depends on whether sponsor switching costs (regulatory familiarity with the CRO, audit history, FDA inspection record) prove higher than the cost-savings pitch can overcome. That is a perishable advantage if incumbents respond with their own platform investments.
The most acute exposure is on the regulatory and trial-quality dimension where the legacy CROs have decades of inspection history and Vial does not yet have a comparable public record. Medable's pure-software posture means it can sell into incumbent CROs as a platform layer, a channel Vial cannot easily address while operating its own services business. Science 37, as a public company, has visible financials that allow sponsors and partners to underwrite its viability in a way Vial's private status does not yet permit.
The most plausible 18-month competitive scenario: Vial wins if it can publish credible cycle-time and cost data from completed sponsor trials in oncology and dermatology, converting case studies into a repeatable mid-market biotech sales motion ("winner if Vial publishes verifiable cycle-time deltas of 20% or more on completed Phase 1/2 oncology trials"). Vial loses ground if a legacy CRO acquires or builds a credible decentralized platform and bundles it into existing sponsor relationships at marginal cost ("loser if IQVIA or ICON ships a competitive DCT layer at sponsor-friendly pricing before Vial reaches Series B").
Data Accuracy: YELLOW -- Competitor identities confirmed by CBInsights; relative positioning is analyst inference from public materials.
Opportunity
PUBLIC
If the integrated CRO-plus-pipeline thesis works, Vial could become the default trial operator for the next generation of venture-funded biotechs and, separately, a pharma developer in its own right.
The headline opportunity. The single largest outcome Vial could plausibly become is the default CRO for early- and mid-stage biotech sponsors, the layer that hundreds of small drug developers route their Phase 1 and Phase 2 trials through because it is materially cheaper and faster than the legacy alternative. The cited evidence makes that outcome reachable rather than aspirational on three grounds: General Catalyst, a top-tier multi-stage investor, has underwritten the thesis with a $67 million check and a public investment note specifically calling out the inefficiency of incumbents [Crunchbase News; General Catalyst]; the company has already built therapeutic-area depth in three segments (oncology, GI, dermatology) where biotech sponsor demand is concentrated [General Catalyst]; and headcount of roughly 179 as of late 2024 (estimated) suggests Vial is operating at a scale where it can run multiple concurrent sponsor programs rather than a single proof-of-concept trial [LeadIQ].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Default biotech CRO | Vial becomes the standard trial operator for venture-funded biotechs running Phase 1/2 studies in its three core therapeutic areas | Publication of cycle-time and cost data from completed sponsor trials | General Catalyst's public thesis explicitly targets this wedge [General Catalyst] |
| Integrated pipeline owner | The in-house pipeline produces at least one clinical-stage asset that validates the "computationally designed therapeutics" claim | First IND filing or Phase 1 readout from an internal program | Vial's public marketing already positions the company as a developer, not just a CRO [Vial] |
| Site network consolidator | Vial expands the NEXT Oncology-style partnerships into a proprietary multi-site network that incumbent CROs cannot easily replicate | Two to three additional named site network deals | The NEXT Oncology addition was disclosed alongside the $67M round, suggesting it is a deliberate strategy [FierceBiotech] |
What compounding looks like. The flywheel that turns one trial win into the next is operational data: every sponsor trial Vial runs generates cycle-time, recruitment, and protocol-adherence data that can be fed back into both the software platform and the in-house pipeline's trial design. Site network deals such as NEXT Oncology compound the same way, because each new site reduces the marginal cost of recruiting patients for the next sponsor in that therapeutic area [FierceBiotech]. The early evidence that the flywheel is starting is the public expansion of the network alongside the financing, rather than separate from it.
The size of the win. Public-market comparables in the CRO category illustrate the ceiling. IQVIA, the largest publicly traded CRO, has historically traded at a market capitalization in the tens of billions of dollars, and Science 37 went public at a multi-billion-dollar valuation before subsequent compression. Neither figure is sourced in the cited research set for this report, so investors should confirm current numbers independently. Translated into a Vial-specific scenario, if the "default biotech CRO" path plays out and the company captures a meaningful share of early-phase trial spend from venture-funded biotech sponsors, the outcome could plausibly be a multi-billion-dollar enterprise on a multi-year horizon (scenario, not a forecast). The integrated-pipeline scenario is harder to size because a single successful internal asset can change the company's value profile entirely, and a single clinical failure can compress it just as quickly.
Data Accuracy: YELLOW -- Scenario plausibility anchored in General Catalyst, Crunchbase News, and FierceBiotech; comparable valuations referenced as scenario framing only and should be independently confirmed.
Sources
PUBLIC
[Vial] Vial | Hyper Scalable Biotech | https://vial.com
[Crunchbase] Vial - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vial
[Crunchbase News] Vial's $67M Raise Spotlights An Untapped Moneymaker For Pharmacies | https://news.crunchbase.com/health-wellness-biotech/vial-clinical-trial-general-catalyst-venture-funding/
[PitchBook] Vial (Biotechnology) 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/462854-53
[General Catalyst] Our Investment in Vial | https://www.generalcatalyst.com/stories/our-investment-in-vial-a-tech-enabled-cro-reimagining-clinical-trials
[LinkedIn] Vial | LinkedIn | https://www.linkedin.com/company/vialtrials
[Startup Intros] Vial: Funding, Team & Investors | https://startupintros.com/orgs/vial
[Forbes] Vial | Company Overview & News | https://www.forbes.com/companies/vial/
[FierceBiotech] Vial reels in $67M in series B fund raising; adds NEXT Oncology to network | https://www.fiercebiotech.com/cro/vial-reels-67m-series-b-fund-raising-adds-next-oncology-network
[CBInsights] Top Science 37 Alternatives, Competitors | https://www.cbinsights.com/company/science-37/alternatives-competitors
[Lever.co] Vial - Scientific Writer (Part-Time) | https://jobs.lever.co/Vial/adc8a46b-bba8-4a78-8537-949ac5e52dc4
[Lever.co] Vial - Clinical Trial Lead/Clinical Research Associate | https://jobs.lever.co/Vial/3395391b-deb7-4d47-a97b-27d3bc586db9
[Lever.co] Vial - Chief of Staff | https://jobs.lever.co/Vial/3696ea29-0a37-489e-8a30-aa9dcffc8999
[Vial job description via drawerrr.com] Vial team backgrounds (Robinhood, Opendoor, Newfront, Apple, Google, Faire, Chime, TPG) | https://vial.com
[LeadIQ] Vial employee count (~179, late 2024) | https://leadiq.com
Articles about Vial
- Vial Wants to Run a Biotech's Phase 2 Trial for Less Than the CRO Down the Street — The San Francisco company has $67M from General Catalyst to rebuild the contract research model around software and a leaner trial site network.